According to filings with the U.S. Securities and Exchange Commission, iQure Pharma is raising $2,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Pawel Zolnierczyk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About iQure Pharma
iQure Pharma is a US-based, global biotech company created by entrepreneurs and former Pharma managers focused on the development of new therapeutics for neuropathic pain, an indication with a high unmet medical need. By focusing on unmet medical needs, we aim to provide patients with an improved quality of life, free of debilitating illnesses. Quality is at the heart of all that we do, because our stakeholders, patients, and healthcare providers deserve the best. Maintaining the highest ethical standards are an integral part of everything we do. As a 100% paper-free company, iQure Pharma strives to help reduce the carbon footprint. We believe in treating all our partners fairly and with respect, making sure everyone benefits from our development efforts.

To learn more about iQure Pharma, visit http://www.iqurepharma.com/

Contact:
Pawel Zolnierczyk, Chief Executive Officer
312-741-1606

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.